CSL Limited (CMXHF) Stock
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About CSL Limited
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company's activities are organized into two primary divisions: CSL Behring and Seqirus. CSL Behring specializes in plasma-derived therapies, delivering essential plasma products and recombinant treatments designed to manage a range of serious conditions such as immunodeficiencies, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. Beyond its therapeutic offerings, this division actively pursues research in both plasma and non-plasma-based treatments, and also generates revenue through licensing and royalties from its intellectual property commercialization. Meanwhile, Seqirus focuses on the manufacturing and distribution of non-plasma biotherapeutics, alongside the development of innovative influenza vaccines and related products. Established in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL Limited is headquartered in AU.
CSL Limited (CMXHF) stock trades at $93.67 with a market capitalization of $44.86B. The stock is valued at a price-to-earnings (P/E) ratio of 32.61, price-to-book of 2.52, price-to-sales of 2.97. Over the past 52 weeks the stock has ranged between $63.84 and $179.00, and currently trades 47.7% below its 52-week high. It pays a dividend yielding 2.78%.
On profitability, CSL Limited generates a return on equity (ROE) of 7.56%, return on capital employed of 12.12%, an operating margin of 25.72%, a net profit margin of 9.17%.
In its most recent fiscal year, CSL Limited reported annual revenue of $15.4B, net profit of $3.0B, revenue has compounded at 11.1% a year over the last five years, profit at 15.6% a year. Profit growing faster than revenue points to expanding margins.
The balance sheet shows a debt-to-equity ratio of 0.67, a current ratio of 2.57, total assets of $39.4B, $2.2B in cash and equivalents.
CMXHF has an average daily trading volume of 2,805 shares, a beta of 0.08 (less volatile than the overall market).
Official website: www.csl.com